Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy (2013)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- Subjects: ANTINEOPLÁSICOS; METÁSTASE NEOPLÁSICA; PROGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Título: European Journal of Cancer
- ISSN: 0959-8049
- Volume/Número/Paginação/Ano: v. 49, supl 2, p. S627, res. 2622, 2013
- Conference titles: European Cancer Congress 2013 Abstract Book
-
ABNT
BRAGHIROLI, M. et al. Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 15 mar. 2026. , 2013 -
APA
Braghiroli, M., Dib, L., Miranda, V., Siqueira, S., Hoff, P. M. G., & Riechelmann, R. (2013). Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529 -
NLM
Braghiroli M, Dib L, Miranda V, Siqueira S, Hoff PMG, Riechelmann R. Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy [Internet]. European Journal of Cancer. 2013 ; 49 S627.[citado 2026 mar. 15 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529 -
Vancouver
Braghiroli M, Dib L, Miranda V, Siqueira S, Hoff PMG, Riechelmann R. Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy [Internet]. European Journal of Cancer. 2013 ; 49 S627.[citado 2026 mar. 15 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
- Quimioterapia sistemica neoadjuvante em câncer epitelial avançado de ovário/peritôneo/tuba uterina: estratégia para obtenção de citorredução ótima
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
